• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

文拉法辛在合并内科疾病的年轻与老年患者中的抗抑郁疗效及心血管安全性

Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders.

作者信息

Zimmer B, Kant R, Zeiler D, Brilmyer M

机构信息

Allegheny General Hospital, Department of Psychiatry, Pittsburgh, PA 15212-5234, USA.

出版信息

Int J Psychiatry Med. 1997;27(4):353-64. doi: 10.2190/UDRD-99CB-T6KH-EDKP.

DOI:10.2190/UDRD-99CB-T6KH-EDKP
PMID:9565731
Abstract

OBJECTIVE

To determine whether venlafaxine exerts a differential effect on blood pressure in young versus old depressed patients.

METHOD

We compared thirty-four consecutive patients treated with 50-250 mg/day venlafaxine for major depressive disorder or another major mood disorder at our medical college's ambulatory neuropsychiatry program. We obtained baseline and follow-up blood pressure measurements. Each patient also received a baseline and final Clinical Global Impressions (CGI) score; global improvement was determined by consensus of two clinicians.

RESULTS

Sixteen nongeriatric patients (age, 13 to 56 years) were compared with eighteen elderly patients (age, 65 to 86 years). Most patients (88%) had serious medical comorbidities or histories. Despite a higher mean daily venlafaxine dosage for patients in the young group, no significant changes in systolic blood pressure were noted in either group. For the older group, we found a non-statistically significant 4.7 mm Hg mean increase in diastolic blood pressure. No patient became hypertensive. We also found a negative correlation between baseline diastolic blood pressure and change in diastolic blood pressure during treatment with venlafaxine. This inverse relationship was statistically significant in the older patients.

CONCLUSIONS

Venlafaxine was not associated with significant, sustained changes in blood pressure in any patient receiving dosages of 50-250 mg/day. Minimal changes in diastolic blood pressure were no more likely to occur in older venlafaxine-treated patients than in younger ones. Higher baseline diastolic blood pressure in older patients, but not in younger ones, seemed to protect against diastolic adrenergic blood pressure effects of venlafaxine.

摘要

目的

确定文拉法辛对年轻与老年抑郁症患者的血压是否有不同影响。

方法

我们比较了在我院门诊神经精神病项目中连续接受50 - 250毫克/日文拉法辛治疗的34例重度抑郁症或其他重度心境障碍患者。我们获取了基线和随访时的血压测量值。每位患者还接受了基线和最终的临床总体印象(CGI)评分;总体改善情况由两名临床医生共同确定。

结果

16例非老年患者(年龄13至56岁)与18例老年患者(年龄65至86岁)进行了比较。大多数患者(88%)有严重的内科合并症或病史。尽管年轻组患者的文拉法辛日均剂量较高,但两组的收缩压均未出现显著变化。对于老年组,我们发现舒张压平均升高4.7毫米汞柱,但无统计学意义。没有患者出现高血压。我们还发现基线舒张压与文拉法辛治疗期间舒张压变化之间存在负相关。这种反向关系在老年患者中具有统计学意义。

结论

在任何接受50 - 250毫克/日剂量文拉法辛治疗的患者中,文拉法辛与血压的显著、持续变化无关。接受文拉法辛治疗的老年患者舒张压的微小变化并不比年轻患者更常见。老年患者而非年轻患者较高的基线舒张压似乎可预防文拉法辛对舒张压的肾上腺素能血压效应。

相似文献

1
Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders.文拉法辛在合并内科疾病的年轻与老年患者中的抗抑郁疗效及心血管安全性
Int J Psychiatry Med. 1997;27(4):353-64. doi: 10.2190/UDRD-99CB-T6KH-EDKP.
2
Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.文拉法辛对血压的影响:对3744例抑郁症患者原始数据的荟萃分析
J Clin Psychiatry. 1998 Oct;59(10):502-8. doi: 10.4088/jcp.v59n1002.
3
Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?双相II型重度抑郁发作患者反复接触抗抑郁药后是否会出现快速减敏现象?
J Affect Disord. 2009 May;115(1-2):234-40. doi: 10.1016/j.jad.2008.07.007. Epub 2008 Aug 9.
4
Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring.文拉法辛或丙咪嗪的亚慢性抗抑郁治疗及其对血压和心率的影响:通过24小时自动监测进行评估
Pharmacopsychiatry. 1996 Mar;29(2):72-8. doi: 10.1055/s-2007-979548.
5
[Effectiveness and security of venlafaxine XR in the treatment of major depression].文拉法辛缓释片治疗重度抑郁症的有效性和安全性
Rev Med Inst Mex Seguro Soc. 2005 Nov-Dec;43(6):473-8.
6
Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.文拉法辛缓释剂治疗重性抑郁障碍的疗效和耐受性。
Psychiatr Danub. 2010 Sep;22(3):413-7.
7
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.缓释文拉法辛治疗非抑郁广泛性焦虑障碍门诊患者的疗效
Am J Psychiatry. 2000 Jun;157(6):968-74. doi: 10.1176/appi.ajp.157.6.968.
8
Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.文拉法辛与锂盐单药治疗双相II型重度抑郁发作的快速循环和非快速循环患者:一项随机、平行组、开放标签试验。
J Affect Disord. 2009 Jan;112(1-3):219-30. doi: 10.1016/j.jad.2008.03.029. Epub 2008 May 16.
9
Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.安非他酮缓释片与文拉法辛缓释片抗抑郁疗效及耐受性的为期八周的安慰剂对照双盲比较
J Psychopharmacol. 2009 Jul;23(5):531-8. doi: 10.1177/0269881108089602. Epub 2008 Jul 17.
10
Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder.高剂量缓释文拉法辛对重度抑郁症患者的心血管影响。
Hum Psychopharmacol. 2007 Apr;22(3):129-33. doi: 10.1002/hup.834.

引用本文的文献

1
Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.移植患者焦虑和抑郁的治疗:药代动力学考量
Clin Pharmacokinet. 2004;43(6):361-94. doi: 10.2165/00003088-200443060-00002.
2
Venlafaxine extended-release: a review of its use in the management of major depression.文拉法辛缓释剂:用于治疗重度抑郁症的综述
CNS Drugs. 2001;15(8):643-69. doi: 10.2165/00023210-200115080-00007.